- Home
- SEED vs LTRN Comparison
SEED vs LTRN Comparison
Compare SEED & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | LTRN |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 10.0M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SEED | LTRN |
|---|---|---|
| Price | $0.93 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 106.8K | ★ 305.2K |
| Earning Date | 05-21-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.60 |
| 52 Week High | $2.12 | $4.34 |
Technical Indicators
Market Signals| Indicator | SEED | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 21.64 |
| Support Level | $0.68 | N/A |
| Resistance Level | $1.08 | $1.96 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 33.55 | 17.25 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.